Cargando…
Clinical Features and Disability Milestones in Multiple System Atrophy and Progressive Supranuclear Palsy
Multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) are an adult-onset progressive neurodegenerative disorder that are known to display diverse clinical features and disease progression. We aim to characterize the clinical features and disease progression in patients with MSA and...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Movement Disorder Society
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4027659/ https://www.ncbi.nlm.nih.gov/pubmed/24868413 http://dx.doi.org/10.14802/jmd.12010 |
_version_ | 1782316977046421504 |
---|---|
author | Lee, Sang-Wook Koh, Seong-Beom |
author_facet | Lee, Sang-Wook Koh, Seong-Beom |
author_sort | Lee, Sang-Wook |
collection | PubMed |
description | Multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) are an adult-onset progressive neurodegenerative disorder that are known to display diverse clinical features and disease progression. We aim to characterize the clinical features and disease progression in patients with MSA and PSP by using a number of relevant disability milestones in Koreans. Forty-one patients with MSA and 14 patients with PSP had been enrolled. The mean age at onset of MSA-C, MSA-P and PSP was 56.7 ± 7.8, 62.5 ± 8.0, 68.9 ± 6.1 years respectively. The most commonly reported symptom at disease onset is disequilibrium/dizziness in MSA-C, tremor in MSA-P and frequent falling in PSP. The mean duration of reaching milestones after disease onset in MSA-C were as followings: 20.8 (urinary incontinence), 22.9 (frequent falling), 27.8 (wheelchair bound), 31.8 (dysarthria) and 35.8 months (diagnosis). The mean duration of reaching milestones after disease onset were 22.0 (urinary incontinence), 32.6 (frequent falling and diagnosis), 41.2 (dysarthria), 61.4 months (wheelchair bound) in MSA-P and 16.8 (dysarthria), 21.6 (diagnosis), 21.7 (frequent falling), 24.0 months (wheel chair bound) in PSP. In the case of MSA, dizziness may occur for the first time. Thus, when the patient complains of non-specific dizziness, a follow-up examination to distinguish it from MSA can be helpful. There was a trend for patients with MSA-C to reach more disability milestones than in MSA-P and PSP before diagnosis. It may explain why patients with MSA-C are required more detail history taking and neurologic examination at an earlier stage. |
format | Online Article Text |
id | pubmed-4027659 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | The Korean Movement Disorder Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-40276592014-05-27 Clinical Features and Disability Milestones in Multiple System Atrophy and Progressive Supranuclear Palsy Lee, Sang-Wook Koh, Seong-Beom J Mov Disord Original Article Multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) are an adult-onset progressive neurodegenerative disorder that are known to display diverse clinical features and disease progression. We aim to characterize the clinical features and disease progression in patients with MSA and PSP by using a number of relevant disability milestones in Koreans. Forty-one patients with MSA and 14 patients with PSP had been enrolled. The mean age at onset of MSA-C, MSA-P and PSP was 56.7 ± 7.8, 62.5 ± 8.0, 68.9 ± 6.1 years respectively. The most commonly reported symptom at disease onset is disequilibrium/dizziness in MSA-C, tremor in MSA-P and frequent falling in PSP. The mean duration of reaching milestones after disease onset in MSA-C were as followings: 20.8 (urinary incontinence), 22.9 (frequent falling), 27.8 (wheelchair bound), 31.8 (dysarthria) and 35.8 months (diagnosis). The mean duration of reaching milestones after disease onset were 22.0 (urinary incontinence), 32.6 (frequent falling and diagnosis), 41.2 (dysarthria), 61.4 months (wheelchair bound) in MSA-P and 16.8 (dysarthria), 21.6 (diagnosis), 21.7 (frequent falling), 24.0 months (wheel chair bound) in PSP. In the case of MSA, dizziness may occur for the first time. Thus, when the patient complains of non-specific dizziness, a follow-up examination to distinguish it from MSA can be helpful. There was a trend for patients with MSA-C to reach more disability milestones than in MSA-P and PSP before diagnosis. It may explain why patients with MSA-C are required more detail history taking and neurologic examination at an earlier stage. The Korean Movement Disorder Society 2012-10-30 2012-10 /pmc/articles/PMC4027659/ /pubmed/24868413 http://dx.doi.org/10.14802/jmd.12010 Text en Copyright © 2012 The Korean Movement Disorder Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Lee, Sang-Wook Koh, Seong-Beom Clinical Features and Disability Milestones in Multiple System Atrophy and Progressive Supranuclear Palsy |
title | Clinical Features and Disability Milestones in Multiple System Atrophy and Progressive Supranuclear Palsy |
title_full | Clinical Features and Disability Milestones in Multiple System Atrophy and Progressive Supranuclear Palsy |
title_fullStr | Clinical Features and Disability Milestones in Multiple System Atrophy and Progressive Supranuclear Palsy |
title_full_unstemmed | Clinical Features and Disability Milestones in Multiple System Atrophy and Progressive Supranuclear Palsy |
title_short | Clinical Features and Disability Milestones in Multiple System Atrophy and Progressive Supranuclear Palsy |
title_sort | clinical features and disability milestones in multiple system atrophy and progressive supranuclear palsy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4027659/ https://www.ncbi.nlm.nih.gov/pubmed/24868413 http://dx.doi.org/10.14802/jmd.12010 |
work_keys_str_mv | AT leesangwook clinicalfeaturesanddisabilitymilestonesinmultiplesystematrophyandprogressivesupranuclearpalsy AT kohseongbeom clinicalfeaturesanddisabilitymilestonesinmultiplesystematrophyandprogressivesupranuclearpalsy |